The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms

Overview

Journal Cancer Res

Specialty Oncology

Date 2008 Nov 1

PMID 18974132

Citations 74

Authors

April L Risinger

Evelyn M Jackson

Lisa A Polin

Gregory L Helms

Desiree A LeBoeuf

Patrick A Joe

Elizabeth Hopper-Borge

Richard F Luduena

Gary D Kruh

Susan L Mooberry

Affiliations

Soon will be listed here.

Abstract

The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri. A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the betaIII isotype of tubulin. The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied. Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7. In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR. An isogenic HeLa-derived cell line that expresses the betaIII isotype of tubulin was generated to evaluate the effect of betaIII-tubulin on drug sensitivity. When compared with parental HeLa cells, the betaIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine. In striking contrast, the betaIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides. These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms. The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential.

Citing Articles

Antioxidative and anticancer effects of Tacca chantrieri extract enhancing cisplatin sensitivity in cholangiocarcinoma cells.

Armartmuntree N, Kittirat Y, Promraksa B, Loilome W, Dokduang H, Techasen A PLoS One. 2025; 20(1):e0317111.

PMID: 39820585 PMC: 11737735. DOI: 10.1371/journal.pone.0317111.

Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site.

Choudhary S, Kaku K, Robles A, Hamel E, Mooberry S, Gangjee A Bioorg Med Chem. 2023; 82:117217.

PMID: 36889150 PMC: 10084637. DOI: 10.1016/j.bmc.2023.117217.

Taccalonolides: Structure, semi-synthesis, and biological activity.

Li Y, Du Y, Gao F, Xu J, Zheng L, Liu G Front Pharmacol. 2022; 13:968061.

PMID: 36034793 PMC: 9407980. DOI: 10.3389/fphar.2022.968061.

Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-]pyrimidines as Microtubule Targeting Agents.

Islam F, Doshi A, Robles A, Quadery T, Zhang X, Zhou X Molecules. 2022; 27(1).

PMID: 35011550 PMC: 8747035. DOI: 10.3390/molecules27010321.

Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines.

Morishita J, Nurse P Open Biol. 2021; 11(9):210161.

PMID: 34493069 PMC: 8424300. DOI: 10.1098/rsob.210161.

References

Banerjee A, Roach M, Trcka P, Luduena R . Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. J Biol Chem. 1992; 267(8):5625-30. View

Joe P, Banerjee A, Luduena R . The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton. 2008; 65(6):476-86. DOI: 10.1002/cm.20274. View

Panda D, Miller H, Banerjee A, Luduena R, Wilson L . Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A. 1994; 91(24):11358-62. PMC: 45230. DOI: 10.1073/pnas.91.24.11358. View

Trock B, Leonessa F, Clarke R . Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997; 89(13):917-31. DOI: 10.1093/jnci/89.13.917. View

Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo M, Ishikawa T . Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol. 2005; 4(3):239-46. View

Kamath K, Wilson L, Cabral F, Jordan M . BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005; 280(13):12902-7. DOI: 10.1074/jbc.M414477200. View

Montero A, Fossella F, Hortobagyi G, Valero V . Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005; 6(4):229-39. DOI: 10.1016/S1470-2045(05)70094-2. View

Chu Q, Vincent M, Logan D, Mackay J, Evans W . Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005; 50(3):355-74. DOI: 10.1016/j.lungcan.2005.06.010. View

Hopper E, Belinsky M, Zeng H, Tosolini A, Testa J, Kruh G . Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001; 162(2):181-91. DOI: 10.1016/s0304-3835(00)00646-7. View

10.

Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

11.

Sadava D, Coleman A, Kane S . Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2003; 12(4):301-9. DOI: 10.1081/lpr-120016196. View

12.

Chen Z, Hopper-Borge E, Belinsky M, Shchaveleva I, Kotova E, Kruh G . Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003; 63(2):351-8. DOI: 10.1124/mol.63.2.351. View

13.

Yeh J, Hsu W, Wang J, Ho S, Kao A . Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration. 2003; 70(1):32-5. DOI: 10.1159/000068411. View

14.

Tinley T, Randall-Hlubek D, Leal R, Jackson E, Cessac J, Quada Jr J . Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity. Cancer Res. 2003; 63(12):3211-20. View

15.

Hari M, Yang H, Zeng C, Canizales M, Cabral F . Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003; 56(1):45-56. DOI: 10.1002/cm.10132. View

16.

Leonard G, Fojo T, Bates S . The role of ABC transporters in clinical practice. Oncologist. 2003; 8(5):411-24. DOI: 10.1634/theoncologist.8-5-411. View

17.

Buey R, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I . Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol. 2005; 12(12):1269-79. DOI: 10.1016/j.chembiol.2005.09.010. View

18.

Chiou J, Liang J, Hsu W, Wang J, Ho S, Kao A . Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung. 2004; 181(5):267-73. DOI: 10.1007/s00408-003-1029-7. View

19.

Jordan M, Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4(4):253-65. DOI: 10.1038/nrc1317. View

20.

Hopper-Borge E, Chen Z, Shchaveleva I, Belinsky M, Kruh G . Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 2004; 64(14):4927-30. DOI: 10.1158/0008-5472.CAN-03-3111. View